During the past decade, MVZ für Blut- und Krebserkrankungen conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "MVZ für Blut- und Krebserkrankungen" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "MVZ für Blut- und Krebserkrankungen" are "Advanced Solid Tumors or Hematologic Malignancies" (1 trials) and "Chronic Myeloid Leukemia" (1 trials). Many other conditions were trialed in "MVZ für Blut- und Krebserkrankungen" in a lesser frequency.

Most popular intervention types in "MVZ für Blut- und Krebserkrankungen" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Nilotinib" (1 trials) and "Peginterferon α2b" (1 trials). Other intervention names were less common.

The vast majority of trials in "MVZ für Blut- und Krebserkrankungen" are 2 trials for "All" genders.

Currently, there are NaN active trials in "MVZ für Blut- und Krebserkrankungen". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in MVZ für Blut- und Krebserkrankungen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MVZ für Blut- und Krebserkrankungen, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".